Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erwan Bezard

Showing results (61-70 of 298) with videos related to

Pageof 30
Sort By:
Journal of Parkinson'S Disease|February 20, 2025
Biological definitions of synucleinopathies should be anchored in clinical trajectories and encompass the complex biology of the diseaseDavid Bendetowicz, Vincent Planche, Erwan Bezard, et al.
NPJ Parkinson'S Disease|January 14, 2022
Similar neuronal imprint and no cross-seeded fibrils in α-synuclein aggregates from MSA and Parkinson's diseaseFlorent Laferrière, Stéphane Claverol, Erwan Bezard, et al.
Synapse (New York, N.Y.)|November 20, 2015
Early prenatal exposure to MPTP does not affect nigrostrial neurons in macaque monkeyMathieu Bourdenx, Sandra Dovero, Philippe De Deurwaerdère, et al.
Neurological Research|September 3, 2010
Metabolic activity of the subthalamic nucleus in a primate model of L-dopa-unresponsive parkinsonismPierre-Olivier Fernagut, Quentin Barraud, Erwan Bezard, et al.
Scientific Reports|April 5, 2017
Lack of spontaneous age-related brain pathology in Octodon degus: a reappraisal of the modelMathieu Bourdenx, Sandra Dovero, Marie-Laure Thiolat, et al.
British Journal of Pharmacology|October 25, 2019
Managing Parkinson's disease: moving ON with NOPDaniela Mercatelli, Erwan Bezard, Roberto Eleopra, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 15, 2012
Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson modelJay S Schneider, Elsa Y Pioli, Yang Jianzhong, et al.
CNS & Neurological Disorders Drug Targets|March 31, 2023
Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's DiseaseErwan Bezard, David Gray, Rouba Kozak, et al.
Scientific Reports|August 10, 2017
Mitochondrial division inhibitor-1 is neuroprotective in the A53T-α-synuclein rat model of Parkinson's diseaseSimone Bido, Federico N Soria, Rebecca Z Fan, et al.
Biological Psychiatry|July 13, 2007
Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathwayShuhong Guo, Jingqi Yan, Tangbin Yang, et al.
Pageof 30

Showing results (61-70 of 298) with videos related to

Sort By:
Pageof 30
Journal of Parkinson'S Disease|February 20, 2025
Biological definitions of synucleinopathies should be anchored in clinical trajectories and encompass the complex biology of the diseaseDavid Bendetowicz, Vincent Planche, Erwan Bezard, et al.
NPJ Parkinson'S Disease|January 14, 2022
Similar neuronal imprint and no cross-seeded fibrils in α-synuclein aggregates from MSA and Parkinson's diseaseFlorent Laferrière, Stéphane Claverol, Erwan Bezard, et al.
Synapse (New York, N.Y.)|November 20, 2015
Early prenatal exposure to MPTP does not affect nigrostrial neurons in macaque monkeyMathieu Bourdenx, Sandra Dovero, Philippe De Deurwaerdère, et al.
Neurological Research|September 3, 2010
Metabolic activity of the subthalamic nucleus in a primate model of L-dopa-unresponsive parkinsonismPierre-Olivier Fernagut, Quentin Barraud, Erwan Bezard, et al.
Scientific Reports|April 5, 2017
Lack of spontaneous age-related brain pathology in Octodon degus: a reappraisal of the modelMathieu Bourdenx, Sandra Dovero, Marie-Laure Thiolat, et al.
British Journal of Pharmacology|October 25, 2019
Managing Parkinson's disease: moving ON with NOPDaniela Mercatelli, Erwan Bezard, Roberto Eleopra, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 15, 2012
Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson modelJay S Schneider, Elsa Y Pioli, Yang Jianzhong, et al.
CNS & Neurological Disorders Drug Targets|March 31, 2023
Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's DiseaseErwan Bezard, David Gray, Rouba Kozak, et al.
Scientific Reports|August 10, 2017
Mitochondrial division inhibitor-1 is neuroprotective in the A53T-α-synuclein rat model of Parkinson's diseaseSimone Bido, Federico N Soria, Rebecca Z Fan, et al.
Biological Psychiatry|July 13, 2007
Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathwayShuhong Guo, Jingqi Yan, Tangbin Yang, et al.
Pageof 30